RT Journal Article
SR Electronic
T1 Understanding the interrelationships of type-2 diabetes and hypertension with brain and cognitive health: a UK Biobank study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.17.21266262
DO 10.1101/2021.11.17.21266262
A1 Danielle Newby
A1 Victoria Garfield
YR 2021
UL http://medrxiv.org/content/early/2021/11/19/2021.11.17.21266262.abstract
AB Aims/hypothesis Diabetes and hypertension are associated with poorer cognitive and brain health. Less is known about comorbid diabetes and hypertension and: cognitive and brain health in mid-life. We hypothesised that individuals with both diabetes and hypertension have worse cognitive and brain health.Methods We used the UK Biobank cohort, a population-based study which recruited 500,000 individuals, aged 40-69 years. Type-2 diabetes was assigned using self-report, HbA1c and clinical data, while hypertension was defined based on self-report. Our outcomes included a breadth of brain structural magnetic resonance imaging (MRI) parameters and cognitive function tests in a maximum of 38918 individuals. We tested associations in a cross sectional design firstly between those with diabetes (n = 2043) versus those without (reference category, n = 36875) then we tested associations between comorbid diabetes/hypertension (reference category, n=1283) and our outcomes by comparing this group with those with only diabetes (n=760), hypertension (n=9649) and neither disease (n=27226). Our analytical approach comprised linear regression models, with adjustment for a range of demographic and health factors.Results Those with diabetes had worse overall brain health, as indexed by multiple neuroimaging parameters, with the exception of gFA (white matter integrity) and the amygdala. The largest difference was observed in the pallidum (β=0.179, 95%CI=0.137;0.220). Individuals with diabetes had poorer performance on certain cognitive tests, with the largest difference observed in the symbol digit substitution test (β=0.132, 95%CI=0.079;0.187). Compared to individuals with comorbid diabetes and hypertension, those with only hypertension had better brain health overall, with the largest difference observed in the pallidum (β=0.189, 95%CI=0.241;0.137), while those with only diabetes differed in total grey volume (β=0.150, 95%CI=0.122;0.179). Compared with individuals who had comorbid diabetes and hypertension, those with only diabetes performed distinctly better on the verbal and numeric reasoning task (β=0.129, 95%CI=0.077;0.261), whereas those with only hypertension performed better on the symbol digit substitution task (β=0.117, 95%CI=0.048;0.186)Conclusions/interpretation Individuals with comorbid diabetes and hypertension have worse brain and cognitive health compared to those with only one of these diseases. These findings potentially suggest that prevention of both diabetes and hypertension may delay changes in brain structure, as well as cognitive decline and dementia diagnosis.What is already known about this subject?Diabetes and hypertension are both independently associated with poorer brain health, cognition and increase in dementia risk50% of adults with diabetes also have hypertensionComorbid diabetes and hypertension are associated with excess dementia riskWhat is the key question?Do individuals with both diabetes and hypertension have worse cognitive and brain health?What are the new findings?Individuals with diabetes have poorer brain health and cognitive performance using a breadth of neuroimaging measures and cognitive testsThose with both diabetes and hypertension have worse brain health and cognitive performance (particularly processing speed) compared to those with only hypertensionHow might this impact on clinical practice in the foreseeable future?Prevention of both diabetes and hypertension may help delay changes in brain structure and cognitive decline as well as reduce future dementia risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a discovery award by Dementia's Platform UK (DPUK), by the MRC (MR/L023784/2) awarded to DN, and by Janssen Pharmaceuticals (DN). VG is jointly funded by a grant from Diabetes UK and the British Heart Foundation (15/0005250).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank received ethical approval from the Research Ethics Committee (11/NW/0382). Volunteers gave informed consent for their participation.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUK Biobank is an open access resource available to verified researchers upon application (http://www.ukbiobank.ac.uk/). Analysis syntax is available on request. This research was conducted using the UK Biobank Resource under approved project 43309. https://www.ukbiobank.ac.uk/ ADAlzheimer’s diseaseBMIbody mass indexFAFractional anisotropyMDMean DiffusivityWMHwhite matter hyperintensities